WARRINGTON, Pa., March 11, 2014 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty
biotechnology company dedicated to advancing a new standard of
respiratory critical care, will report fourth quarter 2013
financial results on Thursday, March 13,
2014 before the open of the U.S. financial markets.
The Company will host a conference call and live audio webcast at
10:00 a.m. Eastern Time that same day. During the conference
call, Discovery Labs' management will discuss the 2013 fourth
quarter financial results along with other business updates.
A question-and-answer session will follow managements' remarks.
To access the conference call and participate in the
question-and-answer session, the number for domestic callers is
(877) 870-4263 and for international callers (412) 317-0790.
The conference call passcode is 10041838. The conference call
replay number is (877) 344-7529 or (412) 317-0088 using the same
conference call password listed above.
The live audio webcast of the conference call will be available
on the Discovery Labs website at www.discoverylabs.com. It is
recommended that participants log onto the audio webcast at least
15 minutes prior to the call. A replay of the audio
webcast will be available after the call at the Company's
website.
About Discovery Labs
Discovery Laboratories, Inc. is a
specialty biotechnology company focused on advancing a new standard
in respiratory critical care. Discovery Labs' technology
platform includes its novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally
similar to pulmonary surfactant, and its proprietary drug delivery
technologies being developed to enable efficient delivery of
aerosolized KL4 surfactant and other inhaled therapies.
Discovery Labs' strategy is initially focused on neonatology
and improving the management of respiratory distress syndrome (RDS)
in premature infants. Discovery Labs believes that its RDS product
portfolio has the potential to become the new standard of care for
RDS and, over time, enable the treatment of a significantly greater
number of premature infants who could benefit from surfactant
therapy but are currently not treated.
For more information, please visit the Company's website at
www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.